Clinical Trial: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.
Detailed Summary:
Sponsor: Alexion Pharmaceuticals
Current Primary Outcome: Adverse events and serious adverse events and their severity and relationship to the drug [ Time Frame: 12 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Alexion Pharmaceuticals
Dates:
Date Received: December 4, 2012
Date Started: May 16, 2012
Date Completion:
Last Updated: March 9, 2017
Last Verified: March 2017